Abstract
The IL-36 family belongs to a larger IL-1 superfamily and consists of three agonists (IL-36α/β/γ), one antagonist (IL-36Ra), one cognate receptor (IL-36R) and one accessory protein (IL-1RAcP). The receptor activation follows a two-step mechanism in that the agonist first binds to IL-36R and the resulting binary complex recruits IL-1RAcP. Assembled ternary complex brings together intracellular TIR domains of receptors which activate downstream NF-κB and MAPK signaling. Antagonist IL-36Ra inhibits the signaling by binding to IL-36R and preventing recruitment of IL-1RAcP. Members of IL-36 are normally expressed at low levels. Upon stimulation, they are inducted and act on a variety of cells including epithelial and immune cells. Protease mediated N-terminal processing is needed for cytokine activation. In the skin, the functional role of IL-36 is to contribute to host defense through inflammatory response. However, when dysregulated, IL-36 stimulates keratinocyte and immune cells to enhance the Th17/Th23 axis and induces psoriatic-like skin disorder. Genetic mutations of the antagonist IL-36Ra are associated with occurrence of generalized pustular psoriasis, a rare but life-threatening skin disease. Anti-IL-36 antibodies attenuate IMQ or IL-23 induced skin inflammation in mice, illustrating IL-36’s involvement in mouse model of psoriasis. Other organs such as the lungs, the intestine, the joints and the brain also express IL-36 family members upon stimulation. The physiological and pathological roles of IL-36 are less well defined in these organs than in the skin. In this chapter, current progress on IL-36 protein and biology is reviewed with a discussion on investigative tools for this novel target.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Afonina IS et al (2011) Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1alpha. Mol Cell 44(2):265–278
Agerstam H et al (2015) Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia. Proc Natl Acad Sci U S A 112(34):10786–10791
Agerstam H et al (2016) IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models. Blood 128(23):2683–2693
Ainscough JS et al (2017) Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36gamma. Proc Natl Acad Sci U S A 114(13):E2748–E2757
Aksentijevich I et al (2009) An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 360(23):2426–2437
Alsahebfosoul F et al (2018) Serum level of interleukin 36 in patients with multiple sclerosis. J Immunoassay Immunochem 39(5):558–564
Aoyagi T et al (2017a) IL-36 receptor deletion attenuates lung injury and decreases mortality in murine influenza pneumonia. Mucosal Immunol 10(4):1043–1055
Aoyagi T et al (2017b) Interleukin-36gamma and IL-36 receptor signaling mediate impaired host immunity and lung injury in cytotoxic Pseudomonas aeruginosa pulmonary infection: role of prostaglandin E2. PLoS Pathog 13(11):e1006737
Arkin MR et al (2003) Binding of small molecules to an adaptive protein-protein interface. Proc Natl Acad Sci U S A 100(4):1603–1608
Arkin MR, Tang Y, Wells JA (2014) Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Chem Biol 21(9):1102–1114
Askmyr M et al (2013) Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood 121(18):3709–3713
Bachelez H et al (2019) Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med 380(10):981–983
Bal E et al (2017) Mutation in IL36RN impairs the processing and regulatory function of the interleukin-36-receptor antagonist and is associated with DITRA syndrome. Exp Dermatol
Barton JL et al (2000) A tissue specific IL-1 receptor antagonist homolog from the IL-1 cluster lacks IL-1, IL-1ra, IL-18 and IL-18 antagonist activities. Eur J Immunol 30(11):3299–3308
Belaaouaj A, Kim KS, Shapiro SD (2000) Degradation of outer membrane protein a in Escherichia coli killing by neutrophil elastase. Science 289(5482):1185–1188
Bensen JT et al (2001) Identification of a novel human cytokine gene in the interleukin gene cluster on chromosome 2q12–14. J Interf Cytokine Res 21(11):899–904
Berglof E et al (2003) IL-1Rrp2 expression and IL-1F9 (IL-1H1) actions in brain cells. J Neuroimmunol 139(1–2):36–43
Blumberg H et al (2007) Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med 204(11):2603–2614
Blumberg H et al (2010) IL-1RL2 and its ligands contribute to the cytokine network in psoriasis. J Immunol 185(7):4354–4362
Boutet MA et al (2016) Distinct expression of interleukin (IL)-36alpha, beta and gamma, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn’s disease. Clin Exp Immunol 184(2):159–173
Bozoyan L et al (2015) Interleukin-36gamma is expressed by neutrophils and can activate microglia, but has no role in experimental autoimmune encephalomyelitis. J Neuroinflammation 12:173
Brunner PM et al (2018) Early-onset pediatric atopic dermatitis is characterized by TH2/TH17/TH22-centered inflammation and lipid alterations. J Allergy Clin Immunol 141(6):2094–2106
Buhl AL, Wenzel J (2019) Interleukin-36 in infectious and inflammatory skin diseases. Front Immunol 10:1162
Busfield SJ et al (2000) Identification and gene organization of three novel members of the IL-1 family on human chromosome 2. Genomics 66(2):213–216
Carrier Y et al (2011) Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol 131(12):2428–2437
Chen Z et al (2016) Increased concentrations of soluble B7-H3 and interleukin 36 in bronchoalveolar lavage fluid of children with mycoplasma pneumoniae pneumonia. BMC Infect Dis 16:212
Clancy DM et al (2017) Neutrophil extracellular traps can serve as platforms for processing and activation of IL-1 family cytokines. FEBS J 284(11):1712–1725
Clancy DM et al (2018) Extracellular neutrophil proteases are efficient regulators of IL-1, IL-33, and IL-36 cytokine activity but poor effectors of microbial killing. Cell Rep 22(11):2937–2950
Dale M, Nicklin MJ (1999) Interleukin-1 receptor cluster: gene organization of IL1R2, IL1R1, IL1RL2 (IL-1Rrp2), IL1RL1 (T1/ST2), and IL18R1 (IL-1Rrp) on human chromosome 2q. Genomics 57(1):177–179
Debets R et al (2001) Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2. J Immunol 167(3):1440–1446
Derer A et al (2014) Blockade of IL-36 receptor signaling does not prevent from TNF-induced arthritis. PLoS One 9(8):e101954
Dietrich D, Gabay C (2014) Inflammation: IL-36 has proinflammatory effects in skin but not in joints. Nat Rev Rheumatol 10(11):639–640
Dunn EF et al (2003) High-resolution structure of murine interleukin 1 homologue IL-1F5 reveals unique loop conformations for receptor binding specificity. Biochemistry 42(37):10938–10944
Dunne A, O'Neill LA (2003) The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2003(171):re3
Farooq M et al (2013) Mutation analysis of the IL36RN gene in 14 Japanese patients with generalized pustular psoriasis. Hum Mutat 34(1):176–183
Fields JK, Gunther S, Sundberg EJ (2019) Structural basis of IL-1 family cytokine Signaling. Front Immunol 10:1412
Fonseca-Camarillo G et al (2018) Differential expression of IL-36 family members and IL-38 by immune and nonimmune cells in patients with active inflammatory bowel disease. Biomed Res Int 2018:5140691
Frey S et al (2013) The novel cytokine interleukin-36alpha is expressed in psoriatic and rheumatoid arthritis synovium. Ann Rheum Dis 72(9):1569–1574
Gabay C, Towne JE (2015) Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions. J Leukoc Biol 97(4):645–652
Ganesan R et al (2017) Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies. MAbs 9(7):1143–1154
Gardner JK, Herbst-Kralovetz MM (2018) IL-36gamma induces a transient HSV-2 resistant environment that protects against genital disease and pathogenesis. Cytokine 111:63–71
Ghayur T et al (1997) Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 386(6625):619–623
Gresnigt MS et al (2013) The IL-36 receptor pathway regulates Aspergillus fumigatus-induced Th1 and Th17 responses. Eur J Immunol 43(2):416–426
Gunther S, Sundberg EJ (2014) Molecular determinants of agonist and antagonist signaling through the IL-36 receptor. J Immunol 193(2):921–930
Gunther S et al (2017) IL-1 family cytokines use distinct molecular mechanisms to signal through their shared co-receptor. Immunity 47(3):510–523.e4
Guo J et al (2019) Cathepsin G cleaves and activates IL-36gamma and promotes the inflammation of psoriasis. Drug Des Devel Ther 13:581–588
Harusato A et al (2017) IL-36gamma signaling controls the induced regulatory T cell-Th9 cell balance via NFkappaB activation and STAT transcription factors. Mucosal Immunol 10(6):1455–1467
He WT et al (2015) Gasdermin D is an executor of pyroptosis and required for interleukin-1beta secretion. Cell Res 25(12):1285–1298
Henry CM et al (2016) Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines. Cell Rep 14(4):708–722
Højen JF et al (2019) IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease. Nat Immunol
Irina Khanskaya, J.P., Margaret H Marino, Traci Savall, Jie Li, Marco Londei (2018) A phase 1 study of ANB019, an anti-IL-36 receptor monoclonal antibody, in healthy volunteers. Available from https://www2.anaptysbio.com/wp-content/uploads/ANB019-Phase-1-Study-Poster-EAACI-2018.pdf
Jaras M et al (2010) Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci U S A 107(37):16280–16285
Johnston A et al (2011) IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol 186(4):2613–2622
Kanda T et al (2015) Interleukin(IL)-36alpha and IL-36gamma induce proinflammatory mediators from human colonic subepithelial myofibroblasts. Front Med (Lausanne) 2:69
Kayagaki N et al (2015) Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 526(7575):666–671
Klementiev B et al (2014) Anti-inflammatory properties of a novel peptide interleukin 1 receptor antagonist. J Neuroinflammation 11:27
Kovach MA et al (2016) IL-36gamma is secreted in microparticles and exosomes by lung macrophages in response to bacteria and bacterial components. J Leukoc Biol 100(2):413–421
Kovach MA et al (2017) IL-36gamma is a crucial proximal component of protective type-1-mediated lung mucosal immunity in gram-positive and -negative bacterial pneumonia. Mucosal Immunol 10(5):1320–1334
Kumar S et al (2000) Identification and initial characterization of four novel members of the interleukin-1 family. J Biol Chem 275(14):10308–10314
Lamacchia C et al (2013) The severity of experimental arthritis is independent of IL-36 receptor signaling. Arthritis Res Ther 15(2):R38
Li N et al (2014) Alarmin function of cathelicidin antimicrobial peptide LL37 through IL-36gamma induction in human epidermal keratinocytes. J Immunol 193(10):5140–5148
Li T et al (2019) TGF-beta type 2 receptor-mediated modulation of the IL-36 family can be therapeutically targeted in osteoarthritis. Sci Transl Med 11(491)
Lian LH et al (2012) The double-stranded RNA analogue polyinosinic-polycytidylic acid induces keratinocyte pyroptosis and release of IL-36gamma. J Invest Dermatol 132(5):1346–1353
Lin H et al (2001) Cloning and characterization of IL-1HY2, a novel interleukin-1 family member. J Biol Chem 276(23):20597–20602
Liu X et al (2013) Structural insights into the interaction of IL-33 with its receptors. Proc Natl Acad Sci U S A 110(37):14918–14923
Liu H et al (2017) Staphylococcus aureus Epicutaneous exposure drives skin inflammation via IL-36-mediated T cell responses. Cell Host Microbe 22(5):653–666. e5
Lovenberg TW et al (1996) Cloning of a cDNA encoding a novel interleukin-1 receptor related protein (IL 1R-rp2). J Neuroimmunol 70(2):113–122
Macleod T et al (2016) Neutrophil elastase-mediated proteolysis activates the anti-inflammatory cytokine IL-36 receptor antagonist. Sci Rep 6:24880
Magne D et al (2006) The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes. Arthritis Res Ther 8(3):R80
Mahil SK et al (2017) An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target. Sci Transl Med 9(411)
Malik K et al (2019) Ichthyosis molecular fingerprinting shows profound TH17 skewing and a unique barrier genomic signature. J Allergy Clin Immunol 143(2):604–618
Marrakchi S et al (2011) Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 365(7):620–628
Martin U et al (2009) Externalization of the leaderless cytokine IL-1F6 occurs in response to lipopolysaccharide/ATP activation of transduced bone marrow macrophages. J Immunol 183(6):4021–4030
Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10(2):417–426
Mattii M et al (2013) The balance between pro- and anti-inflammatory cytokines is crucial in human allergic contact dermatitis pathogenesis: the role of IL-1 family members. Exp Dermatol 22(12):813–819
Medina-Contreras O et al (2016) Cutting edge: IL-36 receptor promotes resolution of intestinal damage. J Immunol 196(1):34–38
Medzhitov R et al (1998) MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 2(2):253–258
Mercurio L et al (2018) IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment. Cell Death Dis 9(11):1104
Miller LS et al (2006) MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus. Immunity 24(1):79–91
Milora KA et al (2017) Interleukin-36beta provides protection against HSV-1 infection, but does not modulate initiation of adaptive immune responses. Sci Rep 7(1):5799
Mulero JJ et al (1999) IL1HY1: a novel interleukin-1 receptor antagonist gene. Biochem Biophys Res Commun 263(3):702–706
Mutamba S et al (2012) Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL-1F8 and IL-1F9. Eur J Immunol 42(3):607–617
Nakagawa S et al (2017) Staphylococcus aureus virulent PSMalpha peptides induce keratinocyte Alarmin release to orchestrate IL-17-dependent skin inflammation. Cell Host Microbe 22(5):667–677. e5
Nanjo Y et al (2019) Overlapping roles for interleukin-36 cytokines in protective host defense against murine Legionella pneumophila pneumonia. Infect Immun 87(1)
Ngo VL et al (2018) A cytokine network involving IL-36gamma, IL-23, and IL-22 promotes antimicrobial defense and recovery from intestinal barrier damage. Proc Natl Acad Sci U S A 115(22):E5076–E5085
Nicklin MJ et al (2002) A sequence-based map of the nine genes of the human interleukin-1 cluster. Genomics 79(5):718–725
Nishida A et al (2016) Increased expression of Interleukin-36, a member of the interleukin-1 cytokine family, in inflammatory bowel disease. Inflamm Bowel Dis 22(2):303–314
Onoufriadis A et al (2011) Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet 89(3):432–437
Ozaki K, Leonard WJ (2002) Cytokine and cytokine receptor pleiotropy and redundancy. J Biol Chem 277(33):29355–29358
Qin J et al (2005) SIGIRR inhibits interleukin-1 receptor- and toll-like receptor 4-mediated signaling through different mechanisms. J Biol Chem 280(26):25233–25241
Quiniou C et al (2008) Development of a novel noncompetitive antagonist of IL-1 receptor. J Immunol 180(10):6977–6987
Ramadas RA et al (2011) Interleukin-1 family member 9 stimulates chemokine production and neutrophil influx in mouse lungs. Am J Respir Cell Mol Biol 44(2):134–145
Ramadas RA et al (2012) IL-36alpha exerts pro-inflammatory effects in the lungs of mice. PLoS One 7(9):e45784
Rivers-Auty J et al (2018) Redefining the ancestral origins of the interleukin-1 superfamily. Nat Commun 9(1):1156
Russell SE et al (2016) IL-36alpha expression is elevated in ulcerative colitis and promotes colonic inflammation. Mucosal Immunol 9(5):1193–1204
Saha SS et al (2015) Signal transduction and intracellular trafficking by the interleukin 36 receptor. J Biol Chem 290(39):23997–24006
Scheibe K et al (2017) IL-36R signalling activates intestinal epithelial cells and fibroblasts and promotes mucosal healing in vivo. Gut 66(5):823–838
Scheibe K et al (2019) Inhibiting interleukin 36 receptor signaling reduces fibrosis in mice with chronic intestinal inflammation. Gastroenterology 156(4):1082–1097. e11
Segueni N et al (2015) Limited contribution of IL-36 versus IL-1 and TNF pathways in host response to mycobacterial infection. PLoS One 10(5):e0126058
Sehat M et al (2018) Evaluating serum levels of IL-33, IL-36, IL-37 and gene expression of IL-37 in patients with psoriasis vulgaris. Iran J Allergy Asthma Immunol 17(2):179–187
Shi J et al (2015) Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526(7575):660–665
Sievers F et al (2011) Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal omega. Mol Syst Biol 7:539. https://doi.org/10.1038/msb.2011.75
Smith DE et al (2000) Four new members expand the interleukin-1 superfamily. J Biol Chem 275(2):1169–1175
Song Y et al (2019) Interleukin-36 alpha levels are elevated in the serum and cerebrospinal fluid of patients with neuromyelitis optica spectrum disorder and correlate with disease activity. Immunobiology
Spangler JB et al (2015) Insights into cytokine-receptor interactions from cytokine engineering. Annu Rev Immunol 33:139–167
Su Z et al (2019) IL-36 receptor antagonistic antibodies inhibit inflammatory responses in preclinical models of psoriasiform dermatitis. Exp Dermatol 28(2):113–120
Sullivan GP et al (2018) Identification of small-molecule elastase inhibitors as antagonists of IL-36 cytokine activation. FEBS Open Bio 8(5):751–763
Sundberg TB et al (2014) Small-molecule control of cytokine function: new opportunities for treating immune disorders. Curr Opin Chem Biol 23:23–30
Swindell WR et al (2018) RNA-Seq analysis of IL-1B and IL-36 responses in epidermal keratinocytes identifies a shared MyD88-dependent gene signature. Front Immunol 9:80
Taylor SL et al (2002) Genomic organization of the interleukin-1 locus. Genomics 79(5):726–733
Thomas C, Bazan JF, Garcia KC (2012) Structure of the activating IL-1 receptor signaling complex. Nat Struct Mol Biol 19(4):455–457
Tiwari RL et al (2011) IL-1R-associated kinase-1 mediates protein kinase Cdelta-induced IL-1beta production in monocytes. J Immunol 187(5):2632–2645
Todorovic V et al (2019) Small molecule IL-36gamma antagonist as a novel therapeutic approach for plaque psoriasis. Sci Rep 9(1):9089
Tomuschat C et al (2017) Altered expression of IL36gamma and IL36 receptor (IL1RL2) in the colon of patients with Hirschsprung's disease. Pediatr Surg Int 33(2):181–186
Tortola L et al (2012) Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest 122(11):3965–3976
Towne JE et al (2004) Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J Biol Chem 279(14):13677–13688
Towne JE et al (2011) Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or antagonist (IL-36Ra) activity. J Biol Chem 286(49):42594–42602
Tsutsumi N et al (2014) The structural basis for receptor recognition of human interleukin-18. Nat Commun 5:5340
van de Veerdonk FL et al (2012) IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc Natl Acad Sci U S A 109(8):3001–3005
van de Veerdonk FL et al (2018) Biology of IL-38 and its role in disease. Immunol Rev 281(1):191–196
Vigne S et al (2011) IL-36R ligands are potent regulators of dendritic and T cells. Blood 118(22):5813–5823
Wang P et al (2005) The interleukin-1-related cytokine IL-1F8 is expressed in glial cells, but fails to induce IL-1beta signalling responses. Cytokine 29(6):245–250
Wang D et al (2010) Structural insights into the assembly and activation of IL-1beta with its receptors. Nat Immunol 11(10):905–911
Weinrauch Y et al (2002) Neutrophil elastase targets virulence factors of enterobacteria. Nature 417(6884):91–94
Whitty A, Zhou L (2015) Horses for courses: reaching outside drug-like chemical space for inhibitors of challenging drug targets. Future Med Chem 7(9):1093–1095
Yang CY (2015) Identification of potential small molecule allosteric modulator sites on IL-1R1 ectodomain using accelerated conformational sampling method. PLoS One 10(2):e0118671
Yi G et al (2016) Structural and functional attributes of the Interleukin-36 receptor. J Biol Chem 291(32):16597–16609
Yoon DY, Dinarello CA (1998) Antibodies to domains II and III of the IL-1 receptor accessory protein inhibit IL-1 beta activity but not binding: regulation of IL-1 responses is via type I receptor, not the accessory protein. J Immunol 160(7):3170–3179
Zhang J et al (2017) IL-36 induces cytokine IL-6 and chemokine CXCL8 expression in human lung tissue cells: implications for pulmonary inflammatory responses. Cytokine 99:114–123
Zheng P et al (2018) Synthetic human monoclonal antibody targets hIL1 receptor accessory protein chain with therapeutic potential in triple-negative breast cancer. Biomed Pharmacother 107:1064–1073
Zhou L et al (2018) Quantitative ligand and receptor binding studies reveal the mechanism of interleukin-36 (IL-36) pathway activation. J Biol Chem 293(2):403–411
Acknowledgement
The authors thank Dr. W. Blaine Stine, Dr. Ivan R. Correia and Dr. Yao Fan for their feedbacks on the manuscript.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
All authors are employees of AbbVie. The design, study conduct, and financial support for this research were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication.
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Zhou, L., Todorovic, V. (2020). Interleukin-36: Structure, Signaling and Function. In: Atassi, M.Z. (eds) Protein Reviews . Advances in Experimental Medicine and Biology(), vol 21. Springer, Cham. https://doi.org/10.1007/5584_2020_488
Download citation
DOI: https://doi.org/10.1007/5584_2020_488
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-67813-5
Online ISBN: 978-3-030-67814-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)